The APS workshop took place during the morning of  Wednesday 7th December at the EICC, before the main DDL2022 conference.

A number of the scientific and regulatory hurdles that exist for developing and registering new nasally-delivered therapies provide common challenges across the pharmaceutical industry. This meeting represents an opportunity to bring together members of the scientific community across industry and academia to discuss specific biopharmaceutics challenges around the development of nasally administered therapies. Aims of the symposium include exploring the need for a network for regular meetings and collaboration, and the development of a consensus of the state-of-the–art in nasal biopharmaceutics.

The symposium will feature thought-provoking short talks summarising how we currently assess the biopharmaceutical properties and performance of nasal products with a focus on new developments and unmet needs. This will be followed by a facilitated panel discussion to explore current practices, opportunities and challenges in these areas. Any questions regarding the workshop programme may be directed to Ben Forbes, King’s College London ([email protected]).

You can view the presentation slides from each presenter below, by clicking on the title of their talk.